Regulatory news / Area Liver
Normativa europea / Area Liver
EMA opens a public consultation on its Concept paper for the HBV guideline revision
![Immagine News](/media/xuhk5yjv/immagine-regulatory-news.png?anchor=center&mode=crop&width=722&height=442)
The EMA has opened a public consultation on its draft Concept paper on the revision of the guideline on the Clinical evaluation of medicinal products intended for treatment of hepatitis B, with a deadline set on 30 April 2024.
As per the draft concept paper, the scope of the future revision of the guideline could focus on the following points:
- Clinical trial requirements including trials that aim to demonstrate the efficacy of treatments aiming at achieving functional cure, including finite and combination treatment regimens.
- Update recommendations for primary efficacy endpoints to include endpoints relevant to achieving viral suppression or functional cure.
- Efficacy and safety considerations when stopping suppressive NUC treatments in clinical trials aimed at evaluating regimens intended to achieve functional cure.
- Considerations specific to the development of agents with novel mechanisms of action.
- Statistical analyses in trials that evaluate finite treatment regimens.
- Definitions of HBV cure, diagnostic criteria, and patient characteristics.
- Editorial and structural changes to improve readability.
The finalisation and adoption of the final concept paper is planned for May 2024.
Reference link: EMA Concept paper on the revision of the guideline on the Clinical evaluation of medicinal products intended for treatment of hepatitis B
Grazie per il tuo feedback!